JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
M. T. Nedelcovych, R. P. Dash, Y. Wu, E. Y. Choi, R. S. Lapidus, P. Majer, D. Abou, M.-F. Penet, A. Nikolopoulou, A. Amor-Coarasa, J. Babich, D. L. Thorek, R. Rais, C. Kratochwil, B. S. Slusher
This paper describes the development of JHU-2545, a prodrug that selectively shields salivary glands and kidneys from PSMA-targeted radiotherapy, improving safety without affecting tumor uptake.
bioRxiv · Feb 15, 2019 · PreprintPharmacology & Toxicology